DDInter1340 DDInter1400
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Omeprazole {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pazopanib
Omeprazole {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Omeprazole {u} (Compound) palliates {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is associated with {v} (Gene) FLT1
FLT1 {u} (Gene) is bound by {v} (Compound) Pazopanib
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pazopanib
Omeprazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is downregulated by {v} (Disease) and {u} (Disease) associated with {v} (Gene) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Omeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Omeprazole {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) regulates {v} (Gene) TSPAN8
TSPAN8 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Omeprazole (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Omeprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Omeprazole (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Pazopanib (Compound)
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may lead to a major life threatening interaction when taken with Pazopanib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may lead to a major life threatening interaction when taken with Pazopanib
Omeprazole (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is associated with FLT1 (Gene) and FLT1 (Gene) is bound by Pazopanib (Compound)
Omeprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Omeprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is downregulated by kidney cancer (Disease) and ABCB1 (Disease) associated with kidney cancer (Gene) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Omeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is downregulated by Pazopanib (Compound)
Omeprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) regulates TSPAN8 (Gene) and TSPAN8 (Gene) is upregulated by Pazopanib (Compound)